Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp192 | Pituitary & endocrine Tumours | ECE2017

Long-term treatment with pegvisomant (Somavert®): Observations from 2090 acromegaly patients followed in ACROSTUDY

vanderLely Aart Jan , Biller Beverly , Brue Thierry , Buchfelder Michael , Ghigo Ezio , Pan kaijie , Jonsson Peter , Lavenberg Joanne , Strasburger Christian J. , Webb Susan , Camacho-Hubner Cecilia , Hey-Hadavi Judith

Introduction: Pegvisomant (PEGV) is approved for the treatment of acromegaly since 2003. This is the second interim analysis of data from ACROSTUDY, with the majority of patients treated for at least five years (yrs).Methods/design: ACROSTUDY is an international, open-label, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of PEGV. Patients were enrolled in the study on an ongoing basis.<...